Global Cardiac Troponin Market Size, Share, and COVID-19 Impact Analysis, By Type (Troponin T and Troponin I), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Setting (Laboratory Testing and Point-Of-Care (POC) Testing), By End User (Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings & Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Cardiac Troponin Market Insights Forecasts to 2035

• The Global Cardiac Troponin Market Size Was Estimated at USD 3.17 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.95% from 2025 to 2035
• The Worldwide Cardiac Troponin Market Size is Expected to Reach USD 7.35 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The global cardiac troponin market size was worth around USD 3.17 billion in 2024 and is predicted to grow to around USD 7.35 billion by 2035 with a compound annual growth rate (CAGR) of 7.95% from 2025 to 2035. The increasing incidence of cardiovascular diseases, technological advancements in troponin testing, and adoption of point-of-care testing are driving the cardiac troponin market globally.  

 

Market Overview

The cardiac troponin market is an industry emphasizing the development, manufacturing, and distribution of tests and assays used for detecting and measuring cardiac troponin levels in the blood. Cardiac troponin (cTn) is a set of regulatory proteins unique to cardiac muscle, plays a crucial role in muscle contraction and relaxation. Further, it serves as a specific biomarker for myocardial damage for the diagnosis of myocardial infarction (MI). The growing technological advancement in the development of fully automated lab systems for improving the efficiency and turnover time for troponin testing by eliminating manual errors, and to scale up testing capacities simultaneously. Further, emphasis on developing innovative products that enhance diagnostic ability as well as the accuracy of troponin tests. Integration of AI and machine learning into troponin testing enables the detection of even minuscule elevations in troponin levels during the early stages of a suspected heart attack. These technological advancements are escalating the market growth opportunities.

 

Report Coverage

This research report categorizes the cardiac troponin market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the cardiac troponin market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the cardiac troponin market.

 

Driving Factors

The growing prevalence of cardiovascular diseases is driving the demand for cardiac troponin for optimizing risk stratification in patients with chronic coronary artery disease. Technological advancements in troponin testing for improved speed, sensitivity, and accuracy for detecting myocardial infarction are propelling the market growth. In addition, the evolution of troponin assays, including the adoption of point of care testing POCT hs-cTn is anticipated to propel the market for cardiac troponin.

 

Restraining Factors

The lack of sensitivity of conventional assays for detecting the presence of small amounts of this protein is restraining the cardiac troponin market. Further, the stringent regulatory requirements and increased raw material prices that increase the overall production cost of the device are restraining the market growth.

 

Market Segmentation

The cardiac troponin market share is classified into type, indication, setting, and end user.

• The troponin I segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the cardiac troponin market is divided into troponin T and troponin I. Among these, the troponin I segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Cardiac troponin I (cTnI) is a single isoform of cardiac muscle tissue. Other than myocardial infarction, other causes of raised troponin include chronic kidney failure, heart failure, subarachnoid haemorrhage, and pulmonary embolus. Further, in veterinary medicine, ionotropic toxicity is found in cattle due to increased cTnI, which is responsible for MI. The growing advancement in troponin I diagnostic testing, including POC testing, aids in propelling market growth.

 

• The laboratory testing segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the setting, the cardiac troponin market is divided into laboratory testing and point-of-care (POC) testing. Among these, the laboratory testing segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Troponin testing is mainly used for the diagnosis of heart attacks. Estimating the amount of troponin in the blood helps in evaluating how much heart has sustained. The detailed analysis provided by laboratory testing as compare to other tests, is driving the segmental market demand.

 

• The acute coronary syndrome segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the indication, the cardiac troponin market is divided into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. Among these, the acute coronary syndrome segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Acute coronary syndrome is highly sensitive to cardiac troponin levels. The testing is essential for diagnostic workup and management of acute coronary syndromes (ACS). The growing prevalence of acute coronary syndrome is responsible for driving the market demand.

 

• The hospitals & clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the predicted timeframe.

Based on the end user, the cardiac troponin market is divided into hospitals & clinics, diagnostic laboratories, and homecare settings & others. Among these, the hospitals & clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the predicted timeframe. An increasing adoption of cardiac troponin tests by healthcare providers, as well as growing hospitalization rates, are driving the cardiac troponin market in the hospitals & clinics segment.

 

Regional Segment Analysis of the Cardiac Troponin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the cardiac troponin market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is anticipated to hold the largest share of the cardiac troponin market over the predicted timeframe. The increasing prevalence of cardiovascular disease in the US, along with an increasing product approvals by the regulatory bodies, aids in propelling the cardiac troponin market. The heightened demand for troponin testing among COVID-19 patients, significantly driving the market growth.

 

Asia Pacific is expected to grow at a rapid CAGR in the cardiac troponin market during the forecast period. The concerns regarding the increasing number of deaths due to cardiovascular diseases in East Asian countries like Japan, China, and Taiwan are driving the market demand for cardiac troponin. An increasing awareness regarding cardiac disease management programs is contributing to promoting market growth.

 

Europe is anticipated to hold a significant share of the cardiac troponin market during the predicted timeframe. The presence of key market players, including F. Hoffmann-La Roche Ltd., Eurolyser Diagnostica GmbH, and others, is responsible for the cardiac troponin market. Further, increasing funds from private and public organizations for conducting research and clinical trials in biomarker testing is driving the market.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the cardiac troponin market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• F. Hoffmann-La Roche Ltd.
• bioMérieux SA
• Abbott
• Siemens Healthineers AG
• Eurolyser Diagnostica GmbH
• QuidelOrtho (Quidel Corporation)
• PerkinElmer Inc.
• Beckman Coulter, Inc. (Danaher)
• RESPONSE BIOMEDICAL
• LifeSign LLC
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

• In May 2023, Bio-Rad Laboratories launched Cardiac Advanced, a four-level multianalyte cardiac quality control for high-sensitivity troponin testing.

 

• In February 2023, Pathology Queensland (PQ) announced that it had installed its highly sensitive cardiac troponin (hs-cTnl) assay.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the cardiac troponin market based on the below-mentioned segments: 

Global Cardiac Troponin Market, By Type

• Troponin T
• Troponin I

 

Global Cardiac Troponin Market, By Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others

 

Global Cardiac Troponin Market, By Setting

• Laboratory Testing
• Point-Of-Care (POC) Testing

 

Global Cardiac Troponin Market, By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare Settings & Others

 

Global Cardiac Troponin Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa